Transcatheter valve therapy has evolved as an established field in clinical practice, with proved effectiveness of improving survival and quality of life in patients deemed inoperable or at high risk for surgical valve replacement. Over the past twenty years, PCR Organization has been helping the cardiovascular community to share knowledge, experience and practice; they have successfully guided and promoted transcatheter valve therapy stretching from Europe to the West. However, the development of transcatheter valve therapy is still at its preliminary stage in mainland China and the Asia-Pacific region.
Under the joint-organization of PCR, CIT (China Interventional Therapeutics), and West China Hospital of Sichuan University, the first edition of “PCR-CIT China Chengdu Valves” (PCCV) is scheduled from 4th - 6th November, 2016 in Chengdu, China. It will be organized based on the successful experience of PCR London Valves, under the theme of Transcatheter Aortic Valve Implantation (TAVI). This conference will focus on basic skill training through hands-on practice, live demonstration, academic lectures and case-based discussions. The PCCV course will help improve the ability of doctors in China and the Asia-Pacific region to use this technology and hopefully promote its development for the benefits of the patients.
Welcome to Chengdu!
PCR-CIT China Chengdu Valves Organizing Committee
|Course directors：||Mao Chen||Christoph Naber||Nicolo Piazza|